Giuseppe Fallara1,2, Fredrik Sandin3, Johan Styrke4, Stefan Carlsson5, Ingela Franck Lissbrant6, Johan Ahlgren3, Ola Bratt7,8, Mats Lambe3, Pär Stattin2. 1. Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. 2. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. 3. Regional Cancer Centre, Uppsala/Örebro, Uppsala University Hospital, Uppsala, Sweden. 4. Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. 5. Department of Molecular Medicine and Surgery, Section of Urology, Karolinska Institutet, Stockholm, Sweden. 6. Department of Oncology Institute of Clinical Sciences, the Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden. 7. Department of Urology, Institute of Clinical Science, the Sahlgrenska Academy, Gothenburg University, Sweden. 8. Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Abstract
INTRODUCTION: The first case of COVID-19 in Sweden was diagnosed in late January 2020, the first recommendations against the spread of the virus were released in mid-March, and the peak of the first wave of the pandemic was reached in March-June. The aim of this cross-sectional study was to assess the short-term effects of the first wave of the COVID-19 pandemic on prostate cancer (PCa) diagnosis, staging, and treatment. MATERIALS AND METHODS: Data in the National Prostate Cancer Register (NPCR) of Sweden on newly diagnosed PCa cases and on the number of diagnostic and therapeutic procedures performed between 18 March 2020 and 2 June 2020 were compared with those in the corresponding time periods in 2017-2019, as reported until January 31 of the year after each study period. RESULTS: During the study period in 2020, 36% fewer PCa cases were registered in NPCR compared with the corresponding time period in previous years: 1458 cases in 2020 vs a mean of 2285 cases in 2017-2019. The decrease in new PCa registrations was more pronounced in men above age 75 years, down 51%, than in men aged 70-75, down 37%, and in men below age 70, down 28%. There was no decrease in the number of radical prostatectomies and number of radical radiotherapy courses increased by 32%. CONCLUSIONS: During the peak of the first phase of the COVID-19 pandemic, the number of men diagnosed with PCa in Sweden decreased by one third compared with previous years, whereas there was no decrease in the number of curative treatments.
INTRODUCTION: The first case of COVID-19 in Sweden was diagnosed in late January 2020, the first recommendations against the spread of the virus were released in mid-March, and the peak of the first wave of the pandemic was reached in March-June. The aim of this cross-sectional study was to assess the short-term effects of the first wave of the COVID-19 pandemic on prostate cancer (PCa) diagnosis, staging, and treatment. MATERIALS AND METHODS: Data in the National Prostate Cancer Register (NPCR) of Sweden on newly diagnosed PCa cases and on the number of diagnostic and therapeutic procedures performed between 18 March 2020 and 2 June 2020 were compared with those in the corresponding time periods in 2017-2019, as reported until January 31 of the year after each study period. RESULTS: During the study period in 2020, 36% fewer PCa cases were registered in NPCR compared with the corresponding time period in previous years: 1458 cases in 2020 vs a mean of 2285 cases in 2017-2019. The decrease in new PCa registrations was more pronounced in men above age 75 years, down 51%, than in men aged 70-75, down 37%, and in men below age 70, down 28%. There was no decrease in the number of radical prostatectomies and number of radical radiotherapy courses increased by 32%. CONCLUSIONS: During the peak of the first phase of the COVID-19 pandemic, the number of men diagnosed with PCa in Sweden decreased by one third compared with previous years, whereas there was no decrease in the number of curative treatments.
Entities:
Keywords:
COVID-19; clinical cancer registry; prostate cancer
Authors: Nina N Harke; Christian Wagner; Robert M Hermann; Boris A Hadaschik; Jan Philipp Radtke; Alev Altay-Langguth; Stefan Aufderklamm; Christian Bach; Martina Becker-Schiebe; Andreas Blana; Frank Bruns; Stephan Buse; Stephanie E Combs; Christina L Engels; Emad Ezzibdeh; Marcel Fiedler; Laura-Anna Fischer; Mahmoud Farzat; Alexander Frismann; Matthias M Heck; Christoph Henkenberens; Marie C Roesch; Christoph Käding; Gunther Klautke; Philipp Krausewitz; Markus A Kuczyk; Conrad Leitsmann; Sebastian Lettmaier; Samy Mahjoub; Andreas Manseck; Daniel Medenwald; Andreas Meyer; Oliver Micke; Rudolf Moritz; Marcel Ott; Inga Peters; Sasa Pokupic; Daniel Porres; Felix Preisser; Kathrin Reichel; Andreas Schneider; Christian Schwentner; Sergiu Scobioala; Michael Truss; Daniel Wegener; Felix Wezel; Kay Willborn; Jörn H Witt; Andrea Wittig; Michael Wittlinger; Hendrik A Wolff; Volker Zimmermanns; Hans Christiansen Journal: PLoS One Date: 2022-06-14 Impact factor: 3.752
Authors: Anna L V Johansson; Siri Larønningen; Charlotte Wessel Skovlund; Marnar Fríðheim Kristiansen; Lina Steinrud Mørch; Søren Friis; Tom Børge Johannesen; Tor Åge Myklebust; Anna Skog; David Pettersson; Helgi Birgisson; Anni Virtanen; Nea Malila; Janne Pitkäniemi; Tomas Tanskanen; Laufey Tryggvadóttir; Giske Ursin; Mats Lambe Journal: Int J Cancer Date: 2022-04-25 Impact factor: 7.316
Authors: Hannah Bower; Thomas Frisell; Daniela di Giuseppe; Bénédicte Delcoigne; Gerd-Marfie Ahlenius; Eva Baecklund; Katerina Chatzidionysiou; Nils Feltelius; Helena Forsblad-d'Elia; Alf Kastbom; Lars Klareskog; Elisabet Lindqvist; Ulf Lindström; Carl Turesson; Christopher Sjowall; Johan Askling Journal: RMD Open Date: 2021-12
Authors: Désirée van Deukeren; Berdine L Heesterman; Lianne Roelofs; Lambertus A Kiemeney; J Alfred Witjes; Tineke J Smilde; Geert J L H van Leenders; Luca Incrocci; Ben G L Vanneste; Richard P Meijer; Sabine Siesling; Bart P J van Bezooijen; Katja K H Aben Journal: Cancer Treat Res Commun Date: 2022-04-02